Skip to main content

Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease

Correction to: Arthritis Res Ther

https://doi.org/10.1186/s13075-019-1843-9

Following publication of the original article [1], the authors reported an error in the spelling of Lorenzo Dagna’s name. The authors apologise for the error.

Incorrect spelling:

Loreno Dagna

Correct spelling:

Lorenzo Dagna

The original article [1] has been updated.

Reference

  1. 1.

    Cavalli, et al. Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease. Arthritis Res Ther. 2019;21:54 https://doi.org/10.1186/s13075-019-1843-9.

    Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Giulio Cavalli.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cavalli, G., Tomelleri, A., De Luca, G. et al. Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease. Arthritis Res Ther 21, 69 (2019). https://doi.org/10.1186/s13075-019-1850-x

Download citation